公开(公告)号：US20240361325A1

公开(公告)日：2024-10-31

申请号：US18765866

申请日：2024-07-08

Applicant: Albert Einstein College of Medicine

Inventor： John S. Condeelis ,  Allison S. Harney

IPC: G01N33/574 ,  C07K16/22

CPC classification number: G01N33/57484 ,  C07K16/22 ,  G01N33/574 ,  C07K2317/76 ,  G01N33/57415 ,  G01N2800/50 ,  G01N2800/52

Abstract: Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.

公开(公告)号：US20240361312A1

公开(公告)日：2024-10-31

申请号：US18432672

申请日：2024-02-05

Applicant: UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN

Inventor： Yoshiya TANAKA ,  Satoshi KUBO ,  Minoru SATOH

IPC: G01N33/564 ,  A61K31/57

CPC classification number: G01N33/564 ,  A61K31/57 ,  G01N2800/10 ,  G01N2800/104 ,  G01N2800/52

Abstract: The present invention provides a method for evaluating severity or prognosis of a patient with mixed connective tissue disease, which includes



1) a step of bringing a biological sample separated from a patient with mixed connective tissue disease into contact with a carrier in which an antigen containing one or more of component proteins of survival motor neuron complex or an antigenic partial peptide thereof is immobilized on a solid phase to form a complex of an autoantibody in the biological sample and the antigen immobilized on the solid phase,
2) a step of detecting the autoantibody in the complex of the autoantibody and the immobilized antigen, and
3) a step of associating the patient with a severe mixed connective tissue disease or a poor prognosis when the autoantibody is detected from the biological sample separated from the patient in step 2).

公开(公告)号：US20240360516A1

公开(公告)日：2024-10-31

申请号：US18285435

申请日：2022-04-05

Applicant: Peter MacCallum Cancer Institute

Inventor： Sarah-Jane DAWSON ,  Mark Agnel Frederick DAWSON ,  Sandunie Dineika CHANDRANANDA ,  Paul Sung-Hao YEH

IPC: C12Q1/6886 ,  C12Q1/6869

CPC classification number: C12Q1/6886 ,  C12Q1/6869 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/52

Abstract: The present disclosure relates generally to methods for the analysis of gene expression. In particular, the methods of the present disclosure are based on the measurement of gene expression from fragments of cell-free DNA (cfDNA), which is useful in non-invasive methods for monitoring disease status in cancer patients and in methods for the treatment of cancer patients.

公开(公告)号：US20240360176A1

公开(公告)日：2024-10-31

申请号：US18635162

申请日：2024-04-15

Applicant: Marshall University Research Corporation

Inventor： Juan Sanabria ,  Sandrine Pierre ,  Moumita Banerjee ,  Zijian Xie ,  Joseph Shapiro

IPC: C07K7/08 ,  A61K38/00 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K7/08 ,  C12Q1/6886 ,  G01N33/57438 ,  G01N33/6848 ,  A61K38/00 ,  C07K2319/10 ,  G01N2333/4703 ,  G01N2800/52

Abstract: Methods for treating non-alcoholic steatohepatitis and/or hepatocellular carcinoma include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods and assays for diagnosis or prognosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject are also provided and include the steps of providing a biological sample from the subject, determining an expression level or activity in the sample of at least one biomarker selected from Caveolin-1, Survivin, and SMAC; and comparing the expression level or activity of the at least one biomarker in the sample, if present, to a control expression level or activity of the at least one biomarker. Prophylaxis or treatment of the non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject can then be initiated based on the expression level or activity of Caveolin-1, Survivin, and SMAC in the sample.

公开(公告)号：US20240358761A1

公开(公告)日：2024-10-31

申请号：US18682798

申请日：2022-08-11

Applicant: Sana Biotechnology, Inc.

Inventor： Sonja SCHREPFER

IPC: A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/00 ,  A61K45/06 ,  C07K14/705 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86 ,  C12N15/90 ,  G01N33/68

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  C07K14/70596 ,  C12N9/22 ,  C12N15/111 ,  C12N15/86 ,  C12N15/907 ,  G01N33/6854 ,  A61K2239/25 ,  A61K2239/38 ,  C12N2310/20 ,  C12N2740/15043 ,  G01N2333/70539 ,  G01N2800/24 ,  G01N2800/52

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.

公开(公告)号：US12130289B2

公开(公告)日：2024-10-29

申请号：US17471803

申请日：2021-09-10

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Allan B. Dietz ,  Michael P. Gustafson

IPC: G01N33/569 ,  A61K38/20

CPC classification number: G01N33/56972 ,  A61K38/2013 ,  G01N2800/24 ,  G01N2800/52

Abstract: This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4+ lymphocytes, CD8+ lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14+HLA-DRlo/neg monocytes, and/or CD86+ monocytes per unit volume (e.g., cells per μL or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

公开(公告)号：US20240353426A1

公开(公告)日：2024-10-24

申请号：US18683069

申请日：2022-08-11

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Vinit Mahajan ,  Gabriel Velez ,  Cassie Ann Ludwig

IPC: G01N33/68 ,  A61K31/155 ,  A61K31/573 ,  A61K38/17 ,  A61K39/00

CPC classification number: G01N33/6893 ,  A61K31/155 ,  A61K31/573 ,  A61K38/179 ,  A61K2039/505 ,  G01N2800/042 ,  G01N2800/16 ,  G01N2800/52

Abstract: Compositions, methods, and kits are provided for diagnosing and treating proliferative diabetic retinopathy. The identified biomarkers can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, or monitoring treatment of proliferative diabetic retinopathy. Methods of treating a subject for proliferative diabetic retinopathy are also provided.

公开(公告)号：US12111308B2

公开(公告)日：2024-10-08

申请号：US17147022

申请日：2021-01-12

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： Lalitha Madhavan

IPC: G01N33/50 ,  C12N5/071

CPC classification number: G01N33/5091 ,  C12N5/0625 ,  G01N33/5044 ,  G01N2800/2835 ,  G01N2800/52 ,  G01N2800/60 ,  G01N2800/7009

Abstract: Primary skin fibroblasts obtained from individuals diagnosed with late-onset sporadic Parkinson's disease (PD), were compared to healthy age-matched controls. Fibroblasts from PD subjects had higher growth rates, and appeared distinctly different in terms of morphology and spatial organization in culture, compared to control cells. The PD fibroblasts also exhibited significantly compromised mitochondrial structure and function when assessed via morphological and oxidative phosphorylation assays. Additionally, an increase in baseline macroautophagy levels was seen in cells from PD subjects. Exposure of the skin fibroblasts to physiologically relevant stress, specifically ultraviolet irradiation (UVA), further exaggerated the autophagic dysfunction in the PD cells. Moreover, the PD fibroblasts accumulated higher levels of reactive oxygen species (ROS) coupled with lower cell viability upon UVA treatment. These results highlight primary skin fibroblasts as a patient-relevant model that captures fundamental PD molecular mechanisms, and enable their utility as diagnostic and prognostic biomarkers for PD.

公开(公告)号：US20240329054A1

公开(公告)日：2024-10-03

申请号：US18656427

申请日：2024-05-06

Applicant: Alector LLC

Inventor： Robert PAUL ,  Michael F. WARD ,  Felix Leejia YEH ,  Yijie LIAO ,  Herve RHINN ,  Arnon ROSENTHAL

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  G01N33/6896 ,  G01N2333/70503 ,  G01N2800/2821 ,  G01N2800/52

Abstract: The present disclosure relates generally to biomarkers of activity and/or therapeutic efficacy of anti-CD33 antibodies for the treatment of a disease or injury in an individual, as well as methods related thereto.

公开(公告)号：US20240329046A1

公开(公告)日：2024-10-03

申请号：US18737392

申请日：2024-06-07

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

Inventor： Martin Villalba Gonzalez ,  Ewelina Krzywinska

IPC: G01N33/574

CPC classification number: G01N33/57426 ,  G01N33/57484 ,  G01N2333/70589 ,  G01N2800/52

Abstract: The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.